How HIV modifies its genetic instructions
Epigenetic modification of HIV-1 Cap
This research explores how the HIV virus changes its genetic instructions to keep replicating and causing problems in the body, even when patients are on medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11169872 on NIH RePORTER |
What this research studies
This project dives into the basic science of HIV, looking at how the virus's genetic material (RNA) is modified, specifically through a process called "cap hypermethylation." This modification helps the virus make copies of itself and persist in the body, contributing to ongoing immune system activation. Researchers are also exploring a new type of drug that can block this specific modification, potentially stopping the virus from replicating effectively without leading to drug resistance. Understanding these processes could lead to new ways to control HIV and reduce its long-term effects on the immune system.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit individuals living with HIV by developing a deeper understanding of the virus and potential new therapies.
Not a fit: Patients not living with HIV would not directly benefit from this specific research, as it focuses on the mechanisms of the HIV virus.
Why it matters
Potential benefit: If successful, this work could lead to new anti-HIV medications that target viral replication in a novel way, potentially improving treatment outcomes and reducing chronic immune activation for patients.
How similar studies have performed: This research builds on recent findings about HIV-1 RNA cap hypermethylation, representing a new paradigm in viral regulation, and explores a novel drug approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Boris-Lawrie, Kathleen a. — University of Minnesota
- Study coordinator: Boris-Lawrie, Kathleen a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.